2024
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.
Schuetze S, Ballman K, Heise R, Ganjoo K, Davis E, George S, Burgess M, Choy E, Shepard D, Tinoco G, Hirbe A, Kelly C, Attia S, Deshpande H, Schwartz G, Siontis B, Riedel R, von Mehren M, Kozlowski E, Chen H, Astbury C, Rubin B. A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma. Clinical Cancer Research 2024, 30: 4584-4592. PMID: 38446990, PMCID: PMC11377863, DOI: 10.1158/1078-0432.ccr-23-3817.Peer-Reviewed Original ResearchEpithelioid hemangioendotheliomaMetastatic epithelioid hemangioendotheliomaMedian PFSOS ratesEvidence of tumor progressionPhase 2 trialMedian pain intensityEffects of trametinibMAPK pathwayActivation of MAPK pathwayInhibitor of MEKPalliative benefitPain intensityPain scoresPrimary endpointAssociated with reductionsTrametinibTumor progressionTumor samplesOncogenic driversVascular cancerPatientsPatient safetyResponse ratePFS
2021
P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).
Schuetze S, Ballman K, Ganjoo K, Davis E, Morgan J, Tinoco G, Burgess M, Van Tine B, Choy E, Shepard D, Kelly C, Riedel R, von Mehren M, Siontis B, Attia S, Schwartz G, Deshpande H, Kozlowski E, Chen H, Rubin B. P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE). Journal Of Clinical Oncology 2021, 39: 11503-11503. DOI: 10.1200/jco.2021.39.15_suppl.11503.Peer-Reviewed Original ResearchObjective response ratePhase 2 trialEpithelioid hemangioendotheliomaObjective responseLarge prospective clinical studiesGI adverse effectsMetastatic epithelioid hemangioendotheliomaObjective tumor progressionPrimary trial endpointNausea/vomitingWeeks of therapyBiomarkers of inflammationProspective clinical studyTreatment of patientsClinical Trials NetworkCommon AEsMedian PFSOS ratesPt ageStable diseasePain scoresAdverse eventsMetastatic diseasePain intensityIndolent growth